It is estimated that 20% of 30% of colorectal cancer (CRC) cases are inherited, although the genetic drivers of risk are not well established [1]. Transforming growth factor beta (TGF-β) plays a central role in the development and progression of CRC. TGFBR1*6A (6A) is a common polymorphism of TGFBR1, an in-frame deletion of 3 GCG repeats coding for Alanine (Ala) within the TGFBR1 signal sequence. Wild-type TGFBR1 encodes for 9 Ala (9A) [2]. 6A (rs11466445) is not included in genome-wide association study (GWAS) chips and is commonly missed by next-generation sequencing platforms because of its high content of guanine (G) and cytosine (C) bases, which hamper polymerase chain reaction amplification by formation of secondary structures and the requirement for high melting temperatures. The association of 6A with cancer risk has been investigated in multiple types of cancer, and 6A is part of a haplotype putatively associated with colon cancer risk in humans [3]. The shortcoming of these studies has been the lack of adjustment for genetic ancestry and the investigation of a relatively low number of cases and controls. Here, we report the impact of 6A as a modifier of CRC using a novel knock-in mouse model and extend those findings to humans via a large family-based, case–control study, adjusting for genetic ancestry.